AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials
Breakpoints
Cepheum Tannibor Bactam
Cepheum tannibor bactam, which was developed by Venetatorex. This agent is currently in phase 2 studies looking again at that treatment refactory MAC disease of the lung. It's a bicyclic boronate beta lactamase inhibitor. And so what does that mean? It means it inhibits serine and metallobatal actamases. So they're going to pursue NDA submission 2023 and we'll also start a HAP VAP trial for that.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode